Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis

Fig. 1

Overview of the study design. Screening was only required once, either before part 1, if participating, or before part 2 of the study. The washout period was up to 3 weeks and was only required if serum phosphorus levels were below age-specific KDOQI targets

CC calcium carbonate, KDOQI Kidney Disease Outcomes Quality Initiative, LC lanthanum carbonate, PK pharmacokinetic

Back to article page